Na Cocer Peptides bin rayt am 
1 mɔnt dɔn pas
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
1. Ɔvaviu
Tadalafil, as wan long-acting phosphodiesterase-5 (PDE-5) inhibitor, de gi nyu we fɔ trit difrɛn kɔndishɔn dɛn ɛn fɔ mek di bɔdi wok fayn.
Fig 1 Min chenj frɔm di beslayn, wit 95% kɔnfidɛns intaval (CI), insay di 6 minit wok distans na wik 16 na di tadalafil ɛn plasɛbo grup dɛn.
2. Ifɛkt pan di we aw di blɔd de go
vasodilayshכn mεkanism: insay di mכtalman bכdi, di naytrik כksid (NO) - saykli guanosine mכnofכsfεt (cGMP) - PDE5 signal path de ple wan kכl rol fכ rεgεl di vaskulכr smol mכsul. we di εndoteyl sεl dεm de rilis NO pan stimulashכn, NO de aktibכt guanylate cyclase, we de promuot di kכnvכshכn fכ guanosine triphosphate (GTP) to cGMP. as intasεlulyar sεkכn mεsenja, cGMP de aktibכt protin kinaz G (PKG), we de mek di vasodilayshכn fכ di vaskulכr smol mכsul, inkrεs vaskulכr dayamita, εn di bכdi fכ fכlכ bכku. di mεkanism fכ akshכn fכ Tadalafil na fכ inhεbit PDE5 aktiviti, ridyus cGMP dεgradashכn, we de mεnten hכy lεvεl fכ cGMP insay sεl dεm εn sכstayn in vasodilatory ifekt dεm fכ impruv bכdi sεkyuleshכn.
Efεkt pan Difrεnt Vaskul Bεd Dεm
di pulmonary sirkulεshכn: Insay di pulmonary sirkulεshכn, dεn kin yus Tadalafil bכku bכku wan fכ trit pulmonary arterial hypertension (PAH). pan PAH pasεnshכn dεm, we di pulmonary vaskulכr rεsistεns de inkrεs de mek di rayt vεntrikul woklכd de inkrεs, we in tכn de afekt di kadyak fכnshכn εn sistεmik bכdi sεkyuleshכn. Tadalafil de dilayt di pulmonari vεsεl dεm, i de ridyus di pulmonari vaskulεr rεsistεns, i de mek di rayt vεntrikul aftalכd, i de impruv di pulmonari sεkyuleshכn hεmodaynamiks, i de inkrεs di kadyak autput, we de mek di sikman dεm in εksεsayz tכlerεns εn kwaliti כf layf. PAH pasɛnt dɛn we bin de gɛt 40 mg Tadalafil wan tɛm ɛvride bin gɛt bɔku impɔtant improvement dɛn pan ɛksɛsayz kapasiti ɛn dɛn bin delay di klinik wɔs.
Sistem Sεkyuleshכn: Insay di sistεmik sεkyuleshכn, Tadalafil de εksyεrt bεnεfit ifekt dεm bak pan di bכdi vεsul dεm. i de dilayt di pεriferal atεri dεm, i de ridyus di pεrifεral vaskulεr rεsistεns, εn i de mek di limb bכdi pεrfyushכn bεtε. Fɔ di wan dɛn we gɛt di sik dɛn we de na di vaskul we de na di say we dɛn de, lɛk di klɔdikeshɔn we de apin wan wan tɛm, Tadalafil kin mek di blɔd go ɔp to di mɔsul dɛn we de dɔŋ di an, i kin mek di ischemia simptom dɛn nɔ bɔku we dɛn de du ɛksɛsayz, ɛn i kin mek dɛn ebul fɔ waka distans ɛn mek dɛn ebul fɔ du ɛksɛsayz. Tadalafil kin impruv di korona at blɔd flɔ rizɔv bak ɛn i kin ɛp fɔ mek di mayokardial pɔrfyushɔn bɛtɛ pan di wan dɛn we gɛt korona at sik, pan ɔl we dɛn nid fɔ du mɔ risach fɔ kɔnfɔm dɛn ifɛkt ya.
Maykroskyuleshכn: Maykrosaykulεshכn na imכtant sayt fכ mεtirial εkshεnj bitwin mכtalman tisu dεm εn bכdi. Tadalafil de mek di maykroskyulatori vεsεl dεlayshכn bכku, i de mek di nכmba fכ di opin kapilari dεm go כp, εn i de mek di tisu bכdi pεrfyushכn εn כksijεn saplai bכku. insay sכm stכdi dεm, dεn fכnshכn se afta Tadalafil tritmεnt, maykrosaykulכtכri bכdi fכ fכlכ vεlositi na di skin εn mכsul tisu dεm aksεlεrayt, we de fεsilit fכ smol nyutriεnt dεlivεri εn mεtabolik west rεmov, we de εp fכ mεnten nכmal fysiolojikal fכnshכn fכ di tisu dεm.
3. Aplikeshɔn fɔ impɔtant fizik pefɔmɛns
Fɔ mek yu ebul fɔ bia wit ɛksɛsayz
Di wan dɛn we gɛt at sik we dɛn bɔn wit: Fɔ di wan dɛn we gɛt at sik we dɛn bɔn wit, mɔ di wan dɛn we gɛt wan ventricle function we dɛn dɔn du Fontan ɔpreshɔn, di we aw dɛn kin bia wit ɛksɛsayz afta dɛn dɔn ɔpreshɔn kin go dɔŋ. Tadalafil, tru in vasodilatory ifekt dεm, de ridyus di pulmonari vaskulεr rεsistεns εn sistεmik vaskulεr rεsistεns, i de impruv di kadyak hεmodaynamiks, εn i de inkrεs di kadyak autput, we de gi mכsul dεm mכr כksijεn εn nyutriεnt dεm we i de du εksεsayz. Insay 16 pasɛnt dɛn we dɛn du Fontan ɔpreshɔn, afta dɛn dɔn gɛt Tadalafil tritmɛnt (fɔs 10mg wan tɛm ɛvride, dɔn 10mg ɛvri 12 awa afta 2 wik, fɔ wan totɛl 6 mɔnt), di avɛrej 6 minit wok distans inkri frɔm 418.75m to 439.06m, ɛn di maksimal ɔksijɛn we dɛn tek (VO2 max) inkri frɔm 0.84 L/min to 1.07 L/min, we sho se i dɔn impɔtant pan ɛksɛsayz ɛnjɔymɛnt.
Populeshɔn we gɛt wɛlbɔdi: Tadalafil kin gɛt fayn impak bak pan ɛksɛsayz ɛnjɔymɛnt pan wɛlbɔdi pipul dɛn. Pan ɔl we bɔku bɔku stɔdi dɛn we dɛn dɔn du pan pipul dɛn we gɛt wɛlbɔdi nɔ bɔku naw, sɔm smɔl smɔl stɔdi dɛn sho se Tadalafil kin mek di blɔd go fayn we dɛn de du ɛksɛsayz, i kin mek di mɔsul dɛn gɛt di rayt ɔksijɛn we dɛn de du fizik, i kin mek dɛn taya te, ɛn i kin mek di atlet dɛn wok fayn. Insay sɔm spɔt dɛn we dɛn kin du fɔ bia, di atlet dɛn bin ripɔt se dɛn kin gɛt bɛtɛ kɔmfɔt fɔ blo ɛn dɛn kin ebul fɔ bia wit ɛksɛsayz afta dɛn dɔn yuz Tadalafil; bɔt dɛn nid fɔ du mɔ strɔng sayɛns risach fɔ mek dɛn ebul fɔ kɔnfɔm dɛn tin ya we dɛn dɔn fɛn.
di mכsul dεm we de wok fayn fayn wan: di nכmal mכsul dεm fכ wok de dipכnt pan di bכdi we de fכ bכt di bכdi εn כksijεn. bay we i de mek di bכdi go fayn, Tadalafil kin gi di mכsul dεm mכr כksijεn εn nyutriεnt dεm, we de mek di εnεji mεtabolism. i kin infכlכ di mכsul kכntrikshכn εn rilaks fכnshכn dεm bak bay we i de rεgεl di intasεlulyar signal path dεm. Insay animal ɛkspiriɛns, animal dɛn we dɛn trit wit Tadalafil sho se dɛn mɔsul dɛn gɛt mɔ trɛnk ɛn dɛn ebul fɔ bia. Fɔ di wan dɛn we gɛt mɔsul sik ɔ di mɔsul atrofi we kin mek dɛn rɛst fɔ lɔng tɛm na bed, Tadalafil kin mek di lokal blɔd go fayn, i kin mek di mɔsul dɛn ripɛnt ɛn mek dɛn gɛt nyu layf, ɛn i kin mek di mɔsul dɛn wok fayn.
Impruv di fyzikal pefɔmans ɛvride: Fɔ di pasɛnt dɛn we gɛt erectile dysfunction (ED), Tadalafil nɔ jɔs de impruv di erectile function bɔt i gɛt fayn impak bak pan di ɔl fizik pefɔmɛns ɛn kwaliti fɔ layf. Bɔku tɛm, di wan dɛn we gɛt ED kin gɛt saykilɔjik strɛs bikɔs ɔf dɛn kɔndishɔn, we kin afɛkt di ɛnjɔymɛnt we dɛn gɛt fɔ du ɛvride ɛn di we aw dɛn de du dɛn bɔdi. Tadalafil de mek di blɔd flɔ fayn fayn wan to di penis kɔpɔs kavnɔsam, i de mek di erectile wok bak, ɛn i de mek di sikman dɛn gɛt kɔnfidɛns bak, we de mek dɛn ebul fɔ bi mɔ proaktiv insay ɛvride layf. Apat frɔm dat, fɔ di wan dɛn we gɛt benign prostatic hyperplasia (BPH) ɛn di lɔwa urinary tract symptoms (LUTS), Tadalafil kin mek di urinary function bɛtɛ bay we i de rilaks di smol smol mɔsul dɛn na di prostate ɛn bladder neck, i kin mek di bɔdi nɔ fil fayn we i gɛt prɔblɛm wit di urinary, ɛn dat kin mek di sikman dɛn bɔdi wok ɛn kwaliti layf ɛvride.
4. Sɔmari
Tadalafil de sho se i gɛt impɔtant ifɛkt fɔ mek di blɔd go fayn ɛn fɔ mek di bɔdi wok fayn. Ilɛksɛf na fɔ trit di sik dɛn we de ambɔg di at ɛn di blɔd blɔd lɛk di pulmonary arterial hypertension ɛn peripheral vascular disease, ɔ fɔ mek dɛn ebul fɔ du ɛksɛsayz, fɔ mek di mɔsul dɛn wok fayn, ɛn fɔ mek di bɔdi wok ɛvride pan di wan dɛn we gɛt at sik we dɛn bɔn wit, i de ple impɔtant pat.
Sos dɛn we dɛn pul
[1] Kaku Y, Chiba K, Sato K, ɛn ɔda pipul dɛn. di protεktiv ifekt dεm we tadalafil de gi εgεst cisplatin-indyus sεl dεm we de fכm di sεl dεm[J]. Bayokemik ɛn Bayofizikal Risach Kɔmyunikeshɔn, 2022,603:123-129.DOI:10.1016/j.bbrc.2022.02.113.
[2] Kwak D, Yoo B. Dey Doz fכ 5 mg Tadalafil Sefli Improv Erectile Fכnshכn εn Liva Fכnshכn Enzym in Smokers[J]. J ɔ rnal ov Man in W ɛ lth, 2022,18:150.DOI:10.31083/j.jomh1807150.
[3] Yang Z, Wang L, Tian L, ɛn ɔda pipul dɛn. Tadalafil-lod PLGA maykrosfεr fכ pulmonari administreshכn: prεparashכn εn evalueshכn[J]. Brazilian Jɔnal fɔ Famasiutik Sayns, 2019. Di s://api.semanticscholar.org/KɔpɔsID:214115397. Di wan dɛn we de stɔdi bɔt di Baybul.
[4] Mónica FZ, De Nucci G. Tadalafil fכ di tritmεnt fכ benign prכstatik haypaplasia[J]. Ekspɛkt Opinion Pan Famakotɛrapi, 2019,20(8):929-937.DOI:10.1080/14656566.2019.1589452.
[5] Khajali Z, Peighambari M. M., Lotfian S, ɛn ɔda pipul dɛn. Tadalafil ɛn ɛksɛsayz kapasiti afta fontan ɔpreshɔn[J]. Risich in Kadyovaskyuɛl Mɛdisin, 2018,7:64-68. https://api.semanticscholar.org/CorpusID:81298947, di wan dɛn we de stɔdi bɔt di Baybul.
[6] ENG, Brundage BH, Ghofrani H. A., ɛn ɔda pipul dɛn. Tadalafil Tεrapi fכ Pulmonari Atεrial Haypatεnshכn[J]. Sirkulεshכn, 2009,119:2894-2903. https://api.semanticscholar.org/KɔpɔsID:9916876. Di wan dɛn we de stɔdi bɔt di Baybul.
[7] Coward RM, Carson C. Tadalafil in di tritmεnt fכ εrektil disfכnkshכn[J]. Tɛrapi ɛn Klinik Risk Manejmɛnt, 2008,4:1315-1330. https://api.semanticscholar.org/KɔpɔsID:7054657. Di wan dɛn we de stɔdi bɔt di Baybul.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
